Moreover, while α-FP-L3 is not universally available and has a high cost of surveillance, the combination of α-FP and DCP has shown higher diagnostic accuracy than individual biomarkers and may be a viable strategy in viral hepatitis endemic countries [223]. This evidence concerns the gene ACE and viral hepatitis.